We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:11-20 of 4,316

No Section 8 liability for valid and infringed patent in Nexium proceeding
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • April 18 2018

If a patentee is unsuccessful in a prohibition application under the Patented Medicines (Notice of Compliance) Regulations against a generic entrant


USPTO Says Overlapping Range In Prior Art Insufficient to Invalidate Method of Treatment Patent
  • Dechert LLP
  • USA
  • April 13 2018

Pharmaceutical patents frequently claim treatment methods that utilize a range of amounts or concentrations for the active ingredient or excipients


Health Plans and Pharmacy Benefit Managers - Past and Future
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • April 13 2018

Historically, health plans and pharmacy benefit managers (“PBMs”) have been uncomfortable neighbors. Plans provide drug coverage, but contract out the


As potential trade war looms, nearly 1,300 U.S. imports from China may be subject to additional 25 percent tariffs under Section 301 and U.S. exports to China potentially subject to additional duties
  • Hogan Lovells
  • USA
  • April 6 2018

U.S. imports from China potentially subject to additional duties include certain chemicals, pharmaceutical products, medical devices, rubber, iron


CADTH outlines revisions to biosimilar and pharmaceutical review programmes
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • April 4 2018

In its Common Drug Review Update - Issue 133, the Canadian Agency for Drugs and Technologies in Health announced revisions to its biosimilar and


Patented Medicine Prices Review Board releases March 2018 NEWSletter
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • April 3 2018

The Patented Medicine Prices Review Board (PMPRB) released its March 2018 NEWSletter (the first NEWSletter since July 2017). Highlights include:


Summary of Medicines Co. v. Hospira, Inc.
  • Sughrue Mion PLLC
  • USA
  • April 2 2018

In Medicines Co. v. Hospira, Inc. ("Medicines II"), the Federal Circuit held that a distribution agreement entered by Medicines Company ("MedCo") with


No Section 8 Liability for Valid and Infringed Patent in NEXIUM Proceeding
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • March 29 2018

What happens when a patentee is unsuccessful in a prohibition application under the Patented Medicines (Notice of Compliance) (PMNOC) Regulations


Enforcement and Litigation Strategies: Skadden’s Eighth Annual Pharmaceutical, Biotechnology and Medical Device Seminar
  • Skadden Arps Slate Meagher & Flom LLP
  • USA
  • March 29 2018

On March 15, 2018, Skadden hosted its Eighth Annual Pharmaceutical, Biotechnology and Medical Device Seminar in Palo Alto, California, which focused


PMPRB releases report analysing generic drug pricing
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • March 28 2018

On February 6 2018 the Patented Medicine Prices Review Board (PMPRB) announced the publication of the most recent edition of its series of reports on